Most recent update: Sunday, April 29, 2018 - 14:56

You are here

venousthromboembolism (VTE)

Know the danger signs of CVI and VTE in pregnant patients

A review of the literature on chronic venous insufficiency (CVI) in pregnant women reveals considerable guidance for their treatment. CVI occurs in up to 80% of pregnant women, while around 7 of every 1,000 pregnant mothers face venous thromboembolism (VTE) and pulmonary embolism (PE). Pregnancy causes significant hemodynamic changes within the circulatory system.

FDA approves 10mg dosing for Xarelto for VTE treatment

Janssen Pharmaceuticals has announced that the FDA approved the 10mg once-daily dose of Xarelto (rivaroxaban) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy. This approval follows a FDA Priority Review and is based on data from EINSTEIN CHOICE, the only clinical study to find that a Factor Xa inhibitor, specifically Xarelto, demonstrated superior efficacy in reducing the continued risk of recurrent VTE and with major bleeding rates similar to aspirin.

Height associated with increased risk for venous thromboembolism

A person’s height is associated with increased risk for venous thromboembolism (VTE) according to a study published in the American Heart Association journal, Circulation: Cardiovascular Genetics. In the study, ‘Body Height and Incident Risk of Venous Thromboembolism - A Cosibling Design’, of more than two million Swedish siblings, researchers found that the risk of venous thromboembolism was associated with height, with the lowest risk being in shorter participants.

VTE therapeutics market worth US$3.7 billion by 2025

An increase in sales in the venous thromboembolism (VTE) primary prophylaxis space is expected to drive the growth in the VTE market from US$2.8bn in 2015 to US$3.7bn by 2025, according to a report by GlobalData. The report, ‘PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2025’, forecasts the VTE market, including deep vein thrombosis and pulmonary embolism, to grow at a compound annual growth rate (CAGR) of 2.89% across the seven major markets of the US, France, Germany, Italy, Spain, the UK and Japan.

Subscribe to RSS - venousthromboembolism (VTE)